Intellia Therapeutics (NTLA) Appoints Muna Bhanji to its Board

Intellia Therapeutics, Inc. (NASDAQ: NTLA) today announced the appointment of Muna Bhanji, R.Ph., to its board of directors.

“We welcome Muna whose deep expertise in global commercialization and market access will be critical to Intellia as we expand our leadership position in the field of genome editing and move closer to commercializing potentially curative treatments for people with life-threatening diseases,” said Intellia President and Chief Executive Officer John Leonard, M.D. “We are very fortunate to benefit from Muna’s extensive experience navigating U.S. and global healthcare systems to improve patient access to innovative medicines. We are thrilled with her joining our board and look forward to her many contributions to our future success.”

You May Also Be Interested In

• Virtus Investment Partners names Jack Boyce to its board
• Newmont names ex-BHP finance chief Peter Beaven to its board
• Veeva Systems names Dan Rizzo EVP of sales amid leadership change